Overcoming Bifurcation Instability in High-Repetition-Rate Ho:YLF Regenerative Amplifiers

We demonstrate a Ho:YLF regenerative amplifier (RA) overcoming bifurcation instability and consequently achieving high extraction energies of 6.9 mJ at a repetition rate of 1 kHz with pulse-to-pulse fluctuations of 1.1%. Measurements of the output pulse energy, corroborated by numerical simulations, identify an operation point that allows high-energy pulse extraction at a minimum noise level. Complete suppression of the onset of bifurcation was achieved by gain saturation after each pumping cycle in the Ho:YLF crystal via lowering the repetition rate and cooling the crystal. Even for moderate cooling, a significant temperature dependence of the Ho:YLF RA performance was observed

The determinants of election to the United Nations Security Council

This is the author's accepted manuscript. The final publication is available at Springer via http://dx.doi.org/10.1007/s11127-013-0096-4.The United Nations Security Council (UNSC) is the foremost international body responsible for the maintenance of international peace and security. Members vote on issues of global importance and consequently receive perks—election to the UNSC predicts, for instance, World Bank and IMF loans. But who gets elected to the UNSC? Addressing this question empirically is not straightforward as it requires a model that allows for discrete choices at the regional and international levels; the former nominates candidates while the latter ratifies them. Using an original multiple discrete choice model to analyze a dataset of 180 elections from 1970 to 2005, we find that UNSC election appears to derive from a compromise between the demands of populous countries to win election more frequently and a norm of giving each country its turn. We also find evidence that richer countries from the developing world win election more often, while involvement in warfare lowers election probability. By contrast, development aid does not predict election

QRS micro-fragmentation as a mortality predictor.

AIMS Fragmented QRS complex with visible notching on standard 12-lead electrocardiogram (ECG) is understood to represent depolarization abnormalities and to signify risk of cardiac events. Depolarization abnormalities with similar prognostic implications likely exist beyond visual recognition but no technology is presently suitable for quantification of such invisible ECG abnormalities. We present such a technology. METHODS AND RESULTS A signal processing method projects all ECG leads of the QRS complex into optimized three perpendicular dimensions, reconstructs the ECG back from this three-dimensional projection, and quantifies the difference (QRS 'micro'-fragmentation, QRS-μf) between the original and reconstructed signals. QRS 'micro'-fragmentation was assessed in three different populations: cardiac patients with automatic implantable cardioverter-defibrillators, cardiac patients with severe abnormalities, and general public. The predictive value of QRS-μf for mortality was investigated both univariably and in multivariable comparisons with other risk factors including visible QRS 'macro'-fragmentation, QRS-Mf. The analysis was made in a total of 7779 subjects of whom 504 have not survived the first 5 years of follow-up. In all three populations, QRS-μf was strongly predictive of survival (P < 0.001 univariably, and P < 0.001 to P = 0.024 in multivariable regression analyses). A similar strong association with outcome was found when dichotomizing QRS-μf prospectively at 3.5%. When QRS-μf was used in multivariable analyses, QRS-Mf and QRS duration lost their predictive value. CONCLUSION In three populations with different clinical characteristics, QRS-μf was a powerful mortality risk factor independent of several previously established risk indices. Electrophysiologic abnormalities that contribute to increased QRS-μf values are likely responsible for the predictive power of visible QRS-Mf. KEY QUESTION KEY FINDING TAKE-HOME MESSAGE QRS-μf is a strong predictor of worsened survival. It can be assessed in standard short-term 12-lead electrocardiograms

Stabilization and structural analysis of a membrane-associated hIAPP aggregation intermediate

Membrane-assisted amyloid formation is implicated in human diseases, and many of the aggregating species accelerate amyloid formation and induce cell death. While structures of membrane-associated intermediates would provide tremendous insights into the pathology and aid in the design of compounds to potentially treat the diseases, it has not been feasible to overcome the challenges posed by the cell membrane. Here, we use NMR experimental constraints to solve the structure of a type-2 diabetes related human islet amyloid polypeptide intermediate stabilized in nanodiscs. ROSETTA and MD simulations resulted in a unique \u3b2-strand structure distinct from the conventional amyloid \u3b2-hairpin and revealed that the nucleating NFGAIL region remains flexible and accessible within this isolated intermediate, suggesting a mechanism by which membrane-associated aggregation may be propagated. The ability of nanodiscs to trap amyloid intermediates as demonstrated could become one of the most powerful approaches to dissect the complicated misfolding pathways of protein aggregation

CUL-2^LRR-1 and UBXN-3 drive replisome disassembly during DNA replication termination and mitosis

Replisome disassembly is the final step of DNA replication in eukaryotes, involving the ubiquitylation and CDC48-dependent dissolution of the CMG helicase (CDC45-MCM-GINS). Using Caenorhabditis elegans early embryos and Xenopus laevis egg extracts, we show that the E3 ligase CUL-2(LRR-1) associates with the replisome and drives ubiquitylation and disassembly of CMG, together with the CDC-48 cofactors UFD-1 and NPL-4. Removal of CMG from chromatin in frog egg extracts requires CUL2 neddylation, and our data identify chromatin recruitment of CUL2(LRR1) as a key regulated step during DNA replication termination. Interestingly, however, CMG persists on chromatin until prophase in worms that lack CUL-2(LRR-1), but is then removed by a mitotic pathway that requires the CDC-48 cofactor UBXN-3, orthologous to the human tumour suppressor FAF1. Partial inactivation of lrr-1 and ubxn-3 leads to synthetic lethality, suggesting future approaches by which a deeper understanding of CMG disassembly in metazoa could be exploited therapeutically

The XMM-SERVS Survey: XMM-Newton Point-source Catalogs for the W-CDF-S and ELAIS-S1 Fields

We present the X-ray point-source catalogs in two of the XMM-Spitzer Extragalactic Representative Volume Survey (XMM-SERVS) fields, W-CDF-S (4.6 deg2) and ELAIS-S1 (3.2 deg2), aiming to fill the gap between deep pencil-beam X-ray surveys and shallow X-ray surveys over large areas. The W-CDF-S and ELAIS-S1 regions were targeted with 2.3 and 1.0 Ms of XMM-Newton observations, respectively; 1.8 and 0.9 Ms exposures remain after flare filtering. The survey in W-CDF-S has a flux limit of 1.0 × 10−14 erg cm−2 s−1 over 90% of its area in the 0.5–10 keV band; 4053 sources are detected in total. The survey in ELAIS-S1 has a flux limit of 1.3 × 10−14 erg cm−2 s−1 over 90% of its area in the 0.5–10 keV band; 2630 sources are detected in total. Reliable optical-to-IR multiwavelength counterpart candidates are identified for ≈89% of the sources in W-CDF-S and ≈87% of the sources in ELAIS-S1. A total of 3129 sources in W-CDF-S and 1957 sources in ELAIS-S1 are classified as active galactic nuclei (AGNs). We also provide photometric redshifts for X-ray sources; ≈84% of the 3319/2001 sources in W-CDF-S/ELAIS-S1 with optical-to-near-IR forced photometry available have either spectroscopic redshifts or high-quality photometric redshifts. The completion of the XMM-Newton observations in the W-CDF-S and ELAIS-S1 fields marks the end of the XMM-SERVS survey data gathering. The ≈12,000 pointlike X-ray sources detected in the whole ≈13 deg2 XMM-SERVS survey will benefit future large-sample AGN studies

Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO):Study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III)

Background: Perinatal asphyxia and resulting hypoxic-ischemic encephalopathy is a major cause of death and long-term disability in term born neonates. Up to 20,000 infants each year are affected by HIE in Europe and even more in regions with lower level of perinatal care. The only established therapy to improve outcome in these infants is therapeutic hypothermia. Allopurinol is a xanthine oxidase inhibitor that reduces the production of oxygen radicals as superoxide, which contributes to secondary energy failure and apoptosis in neurons and glial cells after reperfusion of hypoxic brain tissue and may further improve outcome if administered in addition to therapeutic hypothermia. Methods: This study on the effects of ALlopurinol in addition to hypothermia treatment for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO), is a European double-blinded randomized placebo-controlled parallel group multicenter trial (Phase III) to evaluate the effect of postnatal allopurinol administered in addition to standard of care (including therapeutic hypothermia if indicated) on the incidence of death and severe neurodevelopmental impairment at 24 months of age in newborns with perinatal hypoxic-ischemic insult and signs of potentially evolving encephalopathy. Allopurinol or placebo will be given in addition to therapeutic hypothermia (where indicated) to infants with a gestational age ≥ 36 weeks and a birth weight ≥ 2500 g, with severe perinatal asphyxia and potentially evolving encephalopathy. The primary endpoint of this study will be death or severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment at the age of two years. Effects on brain injury by magnetic resonance imaging and cerebral ultrasound, electric brain activity, concentrations of peroxidation products and S100B, will also be studied along with effects on heart function and pharmacokinetics of allopurinol after iv-infusion. Discussion: This trial will provide data to assess the efficacy and safety of early postnatal allopurinol in term infants with evolving hypoxic-ischemic encephalopathy. If proven efficacious and safe, allopurinol could become part of a neuroprotective pharmacological treatment strategy in addition to therapeutic hypothermia in children with perinatal asphyxia. Trial registration: NCT03162653, www.ClinicalTrials.gov, May 22, 2017.</p